GLP-1 Receptor Agonists in Nonalcoholic Fatty Pancreas Disease: Evidence, Mechanisms, and Future Directions
Clinical review for general practice · 19.06.2026 · 7 (4) · 60-65
DOI: 10.47407/kr2026.7.4.00822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 19.06.2026. Verfasst von Ahmed A Abdelmoaty und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Pancreatic steatosis (fatty pancreas) has emerged as a key pathological condition associated with metabolic dysfunction, impaired β-cell function, exocrine insufficiency, and an increased risk of pancreatitis and pancreatic cancer.
Aim
This review synthesizes current preclinical and clinical evidence on the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on pancreatic fat, elucidates the underlying mechanisms, discusses safety concerns, and highlights research gaps. Materials and methods. A narrative literature review was performed using PubMed and Scopus (2010–2025) with the keywords “GLP-1 receptor agonists,” “fatty pancreas,” and “nonalcoholic fatty pancreas disease (NAFPD)”, including both experimental and clinical investigations.
Results
GLP-1 RAs – including liraglutide, semaglutide, dulaglutide, and emerging dual agonists – exert potent metabolic benefits by reducing body weight, visceral adiposity, and hepatic steatosis. Recent MRI-based studies employing proton density fat fraction quantification indicate that GLP-1 RAs can reduce intrapancreatic fat by up to 20–30% after 24 weeks of therapy. These findings suggest a potentially direct role in ameliorating pancreatic steatosis beyond global weight loss effects.
Conclusion
GLP-1 RAs represent a promising therapeutic strategy for mitigating pancreatic steatosis and its systemic metabolic consequences. Nevertheless, clinical evidence remains limited, and the mechanisms underlying pancreatic fat reduction – whether weight-dependent or independent – require further elucidation. Longitudinal, imaging-based randomized controlled trials are urgently needed to establish causality and clarify the full therapeutic potential of GLP-1 RAs in nonalcoholic fatty pancreas disease. Keywords: pancreatic steatosis, nonalcoholic fatty pancreas disease (NAFPD), GLP-1 receptor agonists, liraglutide, semaglutide, intrapancreatic fat.
Zitieren
APA
Abdelmoaty, A. A., Alsadik, M. E., & Abdel-Sater, K. A. (2026). GLP-1 Receptor Agonists in Nonalcoholic Fatty Pancreas Disease: Evidence, Mechanisms, and Future Directions. Clinical review for general practice, 7(4), 60-65. https://doi.org/10.47407/kr2026.7.4.00822
Vancouver
Abdelmoaty AA, Alsadik ME, Abdel-Sater KA. GLP-1 Receptor Agonists in Nonalcoholic Fatty Pancreas Disease: Evidence, Mechanisms, and Future Directions. Clinical review for general practice. 2026;7(4):60-65. doi:10.47407/kr2026.7.4.00822
BibTeX
@article{Abdelmoaty2026,
author = {Abdelmoaty, Ahmed A and Alsadik, Maha E and Abdel-Sater, Khaled A},
title = {GLP-1 Receptor Agonists in Nonalcoholic Fatty Pancreas Disease: Evidence, Mechanisms, and Future Directions},
journal = {Clinical review for general practice},
year = {2026},
volume = {7},
number = {4},
pages = {60--65},
doi = {10.47407/kr2026.7.4.00822}
}
EUVIMED